The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Early Prostate Cancer: Predicting Treatment Response
Official Title: Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment Response
Study ID: NCT03770351
Brief Summary: This study will replicate/validate the risk prediction model developed for the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study in a more diverse patient population to assess generalizability of the model as well as evaluate the relative contribution of the Decipher Prostate Cancer Test and ProstateNext Test from Ambry Genetics, to the risk prediction model for estimating treatment outcomes, and thereby improve personalization of treatment options.
Detailed Description: The study will contribute a replicable model for improving risk prediction from patient characteristics, clinical severity indicators, and genomic tests to aid in personalizing treatment. The proposed registry would also allow future comparisons of the gene expression used in other competing commercial test. The addition of the suggested genomic classifier and its associations with other patient and clinical characteristics will enhance the ability of future studies, analogous to CEASAR, to accurately predict the risk of tumor aggressiveness in prostate cancer.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
University of California, Irvine, Irvine, California, United States
Veterans Affair Long Beach Healthcare System, Long Beach, California, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
University of California, Los Angeles, Los Angeles, California, United States
Veterans Affair West Los Angeles Healthcare System, West Los Angeles, California, United States
Name: Sheldon Greenfield
Affiliation: University of California, Irvine
Role: PRINCIPAL_INVESTIGATOR